Kezar Life Sciences (NASDAQ:KZR – Get Rating) and Cytokinetics (NASDAQ:CYTK – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 84.0% of Kezar Life Sciences shares […]
Kezar Life Sciences (NASDAQ:KZR – Get Rating) had its price objective trimmed by HC Wainwright from $21.00 to $19.00 in a research note published on Friday morning, The Fly reports. Separately, William Blair reiterated a market perform rating on shares of Kezar Life Sciences in a research report on Wednesday, March 15th. Kezar Life Sciences […]
Kezar Life Sciences (NASDAQ:KZR – Get Rating) had its price target lowered by Wells Fargo & Company from $14.00 to $13.00 in a research report report published on Friday, The Fly reports. Several other brokerages have also recently weighed in on KZR. HC Wainwright reduced their price objective on Kezar Life Sciences from $21.00 to […]
Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,300,000 shares, a growth of 8.4% from the March 15th total of 4,890,000 shares. Based on an average daily volume of 939,400 shares, […]
Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) was the recipient of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,890,000 shares, a growth of 13.2% from the February 28th total of 4,320,000 shares. Based on an average daily volume of 714,700 shares, […]